1. Academic Validation
  2. Discovery of PF-5190457, a Potent, Selective, and Orally Bioavailable Ghrelin Receptor Inverse Agonist Clinical Candidate

Discovery of PF-5190457, a Potent, Selective, and Orally Bioavailable Ghrelin Receptor Inverse Agonist Clinical Candidate

  • ACS Med Chem Lett. 2014 Feb 24;5(5):474-9. doi: 10.1021/ml400473x.
Samit K Bhattacharya 1 Kim Andrews 1 Ramsay Beveridge 1 Kimberly O Cameron 1 Chiliu Chen 1 Matthew Dunn 1 Dilinie Fernando 1 Hua Gao 1 David Hepworth 1 V Margaret Jackson 1 Vishal Khot 1 Jimmy Kong 1 Rachel E Kosa 1 Kimberly Lapham 1 Paula M Loria 1 Allyn T Londregan 1 Kim F McClure 1 Suvi T M Orr 1 Jigna Patel 1 Colin Rose 1 James Saenz 1 Ingrid A Stock 1 Gregory Storer 1 Maria VanVolkenburg 1 Derek Vrieze 1 Guoqiang Wang 1 Jun Xiao 1 Yingxin Zhang 1
Affiliations

Affiliation

  • 1 Worldwide Medicinal Chemistry, Cardiovascular and Metabolic Research Unit, Pharmacokinetics, Dynamics, and Metabolism, Primary Pharmacology Group, and Pharmaceutical Sciences, Pfizer Global Research and Development , 620 Memorial Drive, Cambridge, Massachusetts 02139, United States.
Abstract

The identification of potent, highly selective orally bioavailable ghrelin receptor inverse agonists from a spiro-azetidino-piperidine series is described. Examples from this series have promising in vivo pharmacokinetics and increase glucose-stimulated Insulin secretion in human whole and dispersed islets. A physicochemistry-based strategy to increase lipophilic efficiency for ghrelin receptor potency and retain low clearance and satisfactory permeability while reducing off-target pharmacology led to the discovery of 16h. Compound 16h has a superior balance of ghrelin receptor pharmacology and off-target selectivity. On the basis of its promising pharmacological and safety profile, 16h was advanced to human clinical trials.

Keywords

Ghrelin; PF-5190457; diabetes; ghrelin receptor antagonist; ghrelin receptor inverse agonist.

Figures
Products